GH Research (NASDAQ:GHRS) Trading Down 0.1% – Should You Sell?

GH Research PLC (NASDAQ:GHRS)’s stock price dropped 0.1% during trading on Tuesday . The company traded as low as $7.92 and last traded at $8.05. Approximately 20,530 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 79,945 shares. The stock had previously closed at $8.06.

Analysts Set New Price Targets

GHRS has been the subject of a number of recent research reports. JMP Securities reissued a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research note on Thursday, September 5th.

GH Research Trading Up 2.8 %

The firm has a market capitalization of $433.39 million, a PE ratio of -12.43 and a beta of 0.79. The business’s 50 day simple moving average is $8.15 and its 200 day simple moving average is $10.57.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Analysts forecast that GH Research PLC will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP raised its stake in GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,966,726 shares of the company’s stock after buying an additional 656,163 shares during the period. GH Research comprises 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).